Guillain-Barré syndrome.

Area of Science:

• Neurology
• Immunology
• Infectious Diseases

Background:

• Guillain-Barré syndrome (GBS) is a rare immune-mediated polyradiculoneuropathy characterized by rapid, progressive weakness and sensory deficits.
• It often follows an infection, with molecular mimicry to nerve gangliosides implicated, as seen in Campylobacter jejuni infections.
• Despite effective treatments like plasma exchange and IVIg, a significant portion of patients experience residual disability or mortality.

Purpose of the Study:

• To summarize the current understanding of Guillain-Barré syndrome (GBS), including its pathogenesis, diagnosis, and treatment.
• To highlight critical knowledge gaps, particularly concerning pathogenesis after viral infections and the need for diagnostic and prognostic biomarkers.
• To outline future challenges, including developing more effective, personalized, and accessible treatments and preparing for GBS outbreaks.

Main Methods:

• Clinical features are the primary diagnostic basis.
• Cerebrospinal fluid analysis and nerve conduction studies provide supportive diagnostic evidence.
• Review of existing literature and clinical data on GBS pathogenesis, diagnosis, treatment, and outcomes.

Main Results:

• GBS is an immune-mediated neuropathy often triggered by infections, leading to peripheral nerve damage.
• Diagnosis relies on clinical presentation, CSF analysis, and nerve conduction studies.
• Current treatments (PLEX, IVIg) improve outcomes, but ~20% remain unable to walk at 6 months, and ~5% die.

Conclusions:

• Significant knowledge gaps persist regarding GBS pathogenesis, especially post-viral triggers.
• There is an urgent need for specific biomarkers for improved diagnosis, disease monitoring, and outcome prediction.
• Future research must focus on developing affordable, personalized treatments and pandemic preparedness for GBS outbreaks.